Peter H. Krammer

Peter Heinrich Krammer (born in 1946) is a German immunologist and one of the directors of The National Center for Tumor Diseases (NCT),[1] as well as the head of the Division Immunogenetics [2] at the German Cancer Research Center (DKFZ) in Heidelberg. Peter H. Krammer is well known for his research and findings in apoptosis. He and his lab members discovered the CD95 receptor (also known as Fas and APO-1)[3] and many other molecules involved in signaling through the CD95 receptor.

Peter H. Krammer

Life

Krammer studied medicine at the University of Freiburg (Germany), in St.Louis (USA) and in Lausanne (Switzerland) and graduated in 1971. He was a member of the Basel Institute for Immunology in Switzerland between 1973 and 1975, and a member of Max Planck Institute for Immunobiology in Freiburg, Germany in 1976. In 1976, he became an associate at the Institute for Immunology and Genetics at the German Cancer Research Center in Heidelberg. Between 1981 and 1988, he was the acting head and since 1989, he is the head of the Division of Immunogenetics at the German Cancer Research Center.

In 2000, he was one of the founders of Apogenix,[4] a spin-out from the German Cancer Research Center which is a clinical stage biopharmaceutical company developing novel therapeutics by targeting the modulation of apoptosis.

Since 2010, he is also one of the directors of The National Center for Tumor Diseases (NCT).

Peter H. Krammer has more than 400 scientific publications.[5]

Selection of Awards
  • 1991 Kind Phillip Award for Leukemia Research
  • 1995 Robert Koch Prize
  • 1996 The German Cancer Prize
  • 1996 Behring-Kitasato Prize from the Hoechst Japan
  • 1996 Heinz-Ansmann Prize
  • 1996 Meyenburg Prize
  • 1997 Cancer Research Award Wilhelm Warner Foundation
  • 1998 Avery Landsteiner Prize
  • 2000 Ernst Jung Prize for Medicine
  • 2000 Ludwik Hirszfeld Medal of the Polish Society for Exp. and Clin. Immunology
  • 2001 Genius Biotech Award for APOGENIX
  • 2003 Lautenschläger Research Prize
  • 2004 1st Int. Cell Death Society Prize
  • 2005 Career Award of the European Cell Death Organization
  • 2011 German Cancer Aid Prize
  • 2012 Johann-Georg-Zimmermann Medal

Citations
  3. Trauth, BC; Klas, C; Peters, AM; Matzku, S; Möller, P; Falk, W; Debatin, KM; Krammer, PH (1989). "Monoclonal antibody-mediated tumor regression by induction of apoptosis". Science. 245 (4915): 301–5. CiteSeerX 10.1.1.468.8124. doi:10.1126/science.2787530. PMID 2787530.
  4. "Archived copy". Archived from the original on 2013-02-14. Retrieved 2012-05-20.CS1 maint: archived copy as title (link)
gollark: They're not necessary. They could just assign non-essay work.
gollark: Essays < most things.
gollark: Yes, the best way for the evil antimale conspiracy to act was to distribute a vaccine with very rare side effects not discovered in the clinical trials which manifest more in young men.
gollark: You don't actually need general human-level robotics for lots of automation, at least, if you redesign the environment into something which can be handled more easily.
gollark: Robotics seems to be advancing slowly compared to other AI, so it may end up being the case that physical labour is costlier than lots of intellectual work for a while, which would be really weird.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.